Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors
With up to 20 Months of Dosing, Fitusiran Safety and Tolerability Profile Remains Encouraging Once Monthly, Subcutaneou…